Internal Medicine, Endocrinology, Diabetes, & Metabolism · Falls Church, VA
NPI
1447258538
Since 2005
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
3300 Gallows Rd
Falls Church, VA, 22042
Phone (703) 776-4001
Groups this clinician bills Medicare through
Medicare paid, 2024
$45K
563 services
Medicare patients, 2024
305
Average age 74
Drug cost, 2024
$2.4M
6,678 prescriptions
Company payments, 2025
$161
From 4 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Nahrain H Alzubaidi was code 99214 (office e&m - established), 357 times for 222 patients. In total Nahrain H Alzubaidi billed 563 services in 6 codes, and Medicare paid $45K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-12-06.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 357 | 222 | $87.59 | $31K |
| 99213 Office E&M - Established | Office | 159 | 112 | $47.82 | $7,603 |
| 99204 Office E&M - New | Office | 37 | 37 | $132.99 | $4,921 |
By year: 2022 $61K for 676 services; 2023 $62K for 712 services; 2024 $45K for 563 services.
Medicare prescription drug claims, 2024
In 2024, the drug Nahrain H Alzubaidi prescribed most often to Medicare patients was Glipizide Er (Glipizide), with 422 prescriptions and refills. In total Nahrain H Alzubaidi wrote 6,678 Medicare prescriptions that cost $2.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Glipizide Er Glipizide | 422 | 1,234 | 124 | $9,693 |
| Rosuvastatin Calcium Generic | 371 | 1,103 | 118 | $7,820 |
| Levothyroxine Sodium Generic | 351 | 979 | 107 | $4,290 |
| Losartan Potassium Generic | 277 | 814 | 89 | $2,050 |
| Levoxyl Levothyroxine Sodium | 223 | 652 | 69 | $7,665 |
| Metformin Hcl Er Metformin Hcl | 221 | 611 | 79 | $2,068 |
| Synthroid Levothyroxine Sodium | 209 | 615 | 56 | $20K |
| Mounjaro Tirzepatide | 199 | 239 | 39 | $247K |
| Atorvastatin Calcium Generic | 186 | 554 | 69 | $1,965 |
| Amlodipine Besylate Generic | 171 | 512 | 62 | $1,034 |
| Metformin Hcl Generic | 165 | 469 | 53 | $1,338 |
| Simvastatin Generic | 129 | 384 | 40 | $760 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 118 | 323 | 43 | $11K |
| Tresiba Flextouch U-100 Insulin Degludec | 112 | 279 | 40 | $107K |
| Metoprolol Succinate Generic | 110 | 330 | 31 | $1,479 |
Brand drugs: 2,175 claims; generic drugs: 4,238 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Nahrain H Alzubaidi $161 ($161 in general payments such as food, travel and fees) from 4 companies. The largest payer was Daiichi Sankyo Inc. with $113.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.